Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 8;16:28. doi: 10.1186/s12974-019-1420-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — Sema4A treatment causes loss of mature myelinating oligodendrocytes. The brains treated with PBS or Sema4A were sliced and stained for Olig2, a pan-oligodendrocyte marker, or CC1, a mature myelinating oligodendrocyte marker. a PBS injection causes no loss in total oligodendrocyte numbers. b Sema4A injection causes a decrease in total oligodendrocytes. c 50% oligodendrocyte loss is observed after Sema4A treatment. d PBS injection causes no loss in mature myelinating oligodendrocytes. e Sema4A injection causes a decrease of mature myelinating oligodendrocytes by 47% (f). PBS and Sema4A groups each had n = 5. Unpaired t tests were used to compare PBS and Sema4A groups; *p < 0.05